ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
ALNYLAM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$233.29+1.46 (+0.63%)
Close on Oct 19, 2026
- Market cap
- $32.26B
- P/E (TTM)
- 100.1
- Dividend yield
- –
Share price
−$248.38 (−51.57%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ALNYLAM PHARMACEUTICALS, INC. grew revenue 65.2% to $3.71B over fiscal 2025. Free cash flow was $465.38M.
Revenue
$3.71B
+65.2% vs. a year earlier
Operating income
$501.58M
FY2025
Free cash flow
$465.38M
FY2025
EPS, diluted
$2.33
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $32.26B
- P/E ratio
- 100.1
- Price to sales
- 8.69
- Price to book
- 23.82
- Dividend yield
- –
- Free cash flow yield
- 1.44%
Fundamentals
- Revenue
- $3.71B
- Net income
- $733.11M
- EPS, diluted
- $2.33
- Free cash flow
- $465.38M
- Book value per share
- $9.79
- Diluted shares
- 138M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
–
Net income
$733.11M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months